BioCryst (BCRX) Q3 2026 earnings review
Pharmacy stocking lifts BioCryst sales, while its drug plan holds
BioCryst's flagship swelling drug got a one-time lift from a pharmacy switch while its underlying full-year target stood still. Comparable sales of ORLADEYO rose 20% from a year ago to $175 million because its new distributor, CareMed, stocked up on initial inventory. Chief executive Charlie Gayer kept the drug's full-year outlook unchanged, which by our math leaves fourth-quarter sales up just 1% from a year ago.
| ORLADEYO sales from markets owned a year ago | $174.8M +20.4% from a year ago |
|---|---|
| Operating profit, excluding one-offs | $86.5M +70.3% from a year ago |
| Full-year ORLADEYO revenue outlook | Unchanged middle of the range: $635M |
| Full-year operating expense outlook, excluding one-offs | Cut $10M middle of the range: $420M |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because the third-quarter revenue beat came from distributor stocking rather than a pickup in patient demand. On the positive side, shutting down the Birmingham research site let the company trim its full-year operating cost plan by another $10 million, and regulators approved ORLADEYO pellets for older patients.
The question now is whether new pediatric and adult pellet users can reaccelerate ORLADEYO volume once the pharmacy stocking washes out. Either pellets bring in enough new patients to restore double-digit growth, or the franchise settles into single-digit expansion while awaiting 2027 pipeline readouts. Fourth-quarter ORLADEYO revenue and the 2027 outlook will tell.
🐂 Bull Case
Birmingham Shutdown Lowers the Cost Plan Again
BioCryst is closing its research site in Birmingham, Alabama, to cut early-stage research costs and lift profit margins. The rare-disease drugmaker lowered its full-year operating expense outlook, excluding one-offs, by $10 million at the middle of the range to $415 million to $425 million. That follows a $30 million reduction last quarter.
- Operating profit, excluding one-offs: $86.5 million, up 70.3% from a year ago
- Research and development costs, excluding one-offs: 20.6% of comparable sales, down 5.5 percentage points
- General and administrative costs, excluding one-offs: 10.6% of comparable sales, down 3.6 percentage points
- Expected Birmingham savings: $30 million to $35 million a year after $10 million in total cash closure costs
This matters because cost cuts are driving earnings growth while the company waits for late-stage clinical readouts next year. What to watch: the initial 2027 operating expense outlook when the company reports fourth-quarter results. A lower cost base will show how much of the $30 million to $35 million in annual savings drops to the bottom line.
New Pellet Approvals Broaden the HAE Franchise
BioCryst sells ORLADEYO, a daily oral drug that prevents swelling attacks in patients with hereditary angioedema (HAE). Chief executive Charlie Gayer wants to expand the medicine beyond adult capsule users. In August, the biotech group launched oral pellets for children aged 2 to under 12, and early prescriptions ran "ahead of the company’s expectations". In October, regulators also approved the pellets for patients aged 12 and older.
The company also kept its two main pipeline drugs on schedule. BCX17725, an experimental treatment for a severe skin condition called Netherton syndrome, will report early patient data by year-end. Navenibart, a long-acting injectable HAE drug, remains on track for pivotal results in the third quarter of 2027. What to watch: the BCX17725 clinical readout by the end of 2026. Positive data in Netherton syndrome patients would give the company a second rare-disease franchise.
Licensing and Flu Orders Lift Total Revenue
Alongside ORLADEYO, BioCryst earns money from RAPIVAB, an injectable flu treatment, and from licensing European rights to navenibart. The drugmaker raised its full-year total revenue outlook by $20 million at the middle of the range, to $715 million to $730 million, after booking $5.5 million in licensing and other sales this quarter.
The company credited higher revenue from the European navenibart license and larger RAPIVAB orders from international partners. Because ORLADEYO's own outlook stayed flat, these side streams supplied the entire $20 million raise and added non-dilutive cash. What to watch: fourth-quarter licensing and other revenue, which by our math should reach about $13.9 million to meet the middle of the full-year plan. Hitting that figure will confirm the cash boost before partner revenue drops off next year.
🐻 Bear Case
Pharmacy Stocking Drove Q3, Leaving Q4 Flat
Gayer said BioCryst delivered continued growth of ORLADEYO in the third quarter. Sales of the flagship drug from markets the company owned a year ago rose 20.4% to $174.8 million, bouncing back from 10.0% underlying growth in the second quarter.
However, a distributor switch inflated the quarter. In August, BioCryst moved all patient shipments to CareMed, a single specialty pharmacy that "built an initial inventory of ORLADEYO to support patient demand and efficient dispensing". Management kept its full-year ORLADEYO outlook at $625 million to $645 million. By our math, the middle of that range leaves $153.6 million for the fourth quarter, a 12.1% drop from the third quarter and just 1.3% growth from a year ago.
This cuts against the growth story because underlying patient demand is not accelerating. Without the one-time pharmacy stocking, the full-year plan points to near-zero growth by year-end. What to watch: fourth-quarter ORLADEYO revenue against the $153.6 million implied by the middle of the outlook. A result near that mark would show that underlying growth has slowed toward the low single digits.
BioCryst Drops Astria's Second Drug
When BioCryst bought Astria Therapeutics in January 2026 for navenibart, it also acquired STAR-0310, an early-stage drug for atopic dermatitis. After shutting down its own internal discovery labs in June, the company needs outside drugs to refill its pipeline.
This quarter, the company discontinued STAR-0310 "to focus resources on rare diseases" after it failed to find a partner for the program. It also formed a seven-member Scientific Advisory Board to "provide independent guidance and expertise for the successful execution of the external R&D strategy". Scrapping STAR-0310 leaves the pipeline entirely dependent on navenibart and BCX17725 until management buys new assets. What to watch: any licensing deal or acquisition announced alongside the new advisory board. An expensive buyout would strain a balance sheet that already carries $817.3 million in total debt.
Royalties Still Consume a Fifth of Sales
BioCryst funded its earlier development and the Astria buyout with term loans and royalty financing deals, where investors gave upfront cash in exchange for a share of future drug revenue. At the end of September, the company owed $395.6 million on its secured term loan and $421.7 million in royalty financing obligations, leaving a stockholders' deficit of $397.4 million.
In the third quarter, the drugmaker paid $33.7 million in cash on its royalty obligations, which by our math equals 19.3% of ORLADEYO revenue, alongside $21.2 million in total interest expense. That heavy cash drain limits how much operating profit turns into free cash for debt paydown or new drugs. What to watch: quarterly cash paid on royalty obligations in the fourth-quarter report. Until cumulative payments hit the contractual caps late this decade, roughly a fifth of ORLADEYO revenue will keep going to financing partners.
Risks This Quarter Didn't Answer
Four standing concerns around patient demand and patent litigation received no quantitative numbers in the third-quarter earnings release, so they remain open until the conference call or the quarterly filing.
- US paid patient rate: not in the release after sitting at 84% last quarter against an 85% goal; the conference call remarks will show if the typical second-half dip occurred.
- Pediatric pellet prescriptions: described only as ahead of expectations after 47 prescriptions through July; any patient conversion figure on the call would size the launch.
- One-year patient retention and new prescribers: missing from the release; commentary on the call will test whether churn has changed from the historical 40% drop-off.
- Annora generic patent challenge: unmentioned in the release; the legal footnote in the quarterly filing will show if litigation timelines moved.
💲 Other KPIs
Amounts owed by customers rose 10.0% from last quarter and 33.4% from a year ago, outpacing the 13.1% rise in reported revenue. Receivables have climbed for three straight quarters from $106.8 million at year-end, reflecting CareMed's initial inventory stocking at the end of the quarter.
Weighted average diluted shares rose 21.7% from 219.9 million a year ago and 0.9% from 265.2 million last quarter. BioCryst issued roughly 37.3 million shares in January to buy Astria Therapeutics, which holds back per-share profit growth compared with total net income growth.
Cash, restricted cash and investments increased by $22.5 million from $354.0 million in the second quarter and $260.8 million in the first quarter. Operating cash flow turned positive during the period, helping rebuild liquidity after the January acquisition.
🔮 Guidance
Unchanged. The plan still calls for $635 million at the middle of the range, or 12.8% growth from last year's sales excluding Europe. By our math, that leaves $153.6 million for the fourth quarter, down 12.1% from the third quarter and up 1.3% from a year ago as CareMed's initial inventory build does not repeat. In the last two years, full-year sales beat the final outlook midpoint by an average of 1.2%.
Raised. Management lifted the middle of the range by $20 million to $722.5 million, or 21.9% growth against last year's comparable base. By our math, that leaves $167.5 million for the fourth quarter, up 2.6% from a year ago. It is the second raise this year — $0M in Q1, +$55M in Q2, +$20M in Q3 — driven by European navenibart licensing and international RAPIVAB flu orders.
Improved. The company lowered its planned cost range by $10 million at the middle to $420 million, excluding stock-based pay, restructuring and deal costs. By our math, after $290.2 million in the first nine months (excluding cost of goods), the plan leaves $129.8 million for the fourth quarter, up from $92.2 million in the third quarter. This is the second cost reduction this year: $0M, -$30M, -$10M.
❓ Key Questions
How much did CareMed stocking add to Q3 ORLADEYO sales?
The company said ORLADEYO grew from a year ago even without CareMed's initial inventory build, but did not give the dollar size of the stocking. Without that number, investors cannot tell what true patient demand was in the third quarter.
What was the US paid patient rate in Q3?
The share of US patients on paid product sat at 84% last quarter against an 85% target, and management previously noted a typical 1 to 2 percentage point dip in the second half. The press release did not include the third-quarter rate.
How many pediatric pellet prescriptions have converted to paid shipments?
BioCryst reported 47 written prescriptions through July and said third-quarter prescribing ran ahead of expectations. Knowing how many children are now on paid therapy would show whether the pediatric launch can offset slowing adult growth.
Why does the cost plan imply a $130M Q4 spend?
Operating expenses excluding one-offs and cost of goods averaged $96.7 million a quarter in the first nine months. By our math, the $420 million full-year midpoint leaves $129.8 million for the fourth quarter despite the Birmingham closure savings.